Omeros Corporation Reports $28.5M in Net Product Sales for YARTEMLEA in Q2 2026

Omeros Corporation reported significant financial developments in its latest 10-Q filing for the quarter ending June 30, 2026. The company generated $28.5 million in net product sales from its commercial product, YARTEMLEA, during the second quarter, marking a notable increase from zero sales in the same period last year. For the first half of 2026, net revenues reached $38.4 million, reflecting the successful launch of YARTEMLEA, which began distribution in January 2026. The gross revenues for the quarter were $32.2 million, with gross-to-net deductions of approximately 11.5%.

In terms of expenses, Omeros reported total costs of $28.5 million for the second quarter, a decrease from $32.4 million in the prior year. Research and development expenses fell to $13.8 million from $22.0 million year-over-year, primarily due to reduced spending on the MASP-3 program following the sale of zaltenibart to Novo Nordisk. Selling, general, and administrative expenses increased to $13.9 million from $10.3 million, driven by the expansion of the U.S. commercial organization to support YARTEMLEA's launch.

Omeros also made strategic moves in its debt management, repurchasing approximately $30.5 million of its 2029 Notes for a total of $60.2 million, which included accrued interest. This transaction reduced the outstanding principal of the 2029 Notes to approximately $40.3 million. The company recognized a loss of $1.9 million on the extinguishment of these notes during the quarter. As of June 30, 2026, Omeros had cash, cash equivalents, and short-term investments totaling $132.0 million, providing a solid liquidity position to support ongoing operations.

Operationally, Omeros reported that 73 unique accounts had ordered YARTEMLEA by the end of June 2026, representing a 143% increase in ordering accounts since March 31, 2026. The company is actively engaging with all 175 stem-cell transplant centers in the U.S. to drive awareness and adoption of YARTEMLEA. However, the company faced a setback when the European Medicines Agency's Committee for Medicinal Products for Human Use issued a negative opinion on its marketing authorization application for narsoplimab in TA-TMA, prompting Omeros to request a re-examination.

Looking ahead, Omeros expects to continue investing in the development of YARTEMLEA and its other therapeutic programs, including the MASP-2 inhibitor OMS1029 and the oncology program OncotoX-AML. The company anticipates that research and development expenses will increase in the third quarter of 2026 as it ramps up investment in these initiatives. Overall, Omeros remains focused on leveraging its current cash position and product sales to fund its operations and growth strategies in the coming months.